<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48524">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01819428</url>
  </required_header>
  <id_info>
    <org_study_id>NOV120101-201</org_study_id>
    <nct_id>NCT01819428</nct_id>
  </id_info>
  <brief_title>NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma</brief_title>
  <official_title>A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National OncoVenture</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National OncoVenture</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this open-label, single-arm, multi-center phase II trial is to evaluate the
      efficacy and safety of novel pan-HER inhibitor, NOV120101 (Poziotinib), as a first-line
      monotherapeutic agent in patients with lung adenocarcinoma harboring EGFR mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EGFR TKIs are known as more effective and less toxic medications against EGRF mutated
      tumors. However, newly acquired resistance to these inhibitors is the inevitable obstacle in
      continuous treatment with them. To overcome this problem, many new class of TKIs  including
      NOV120101 (Poziotinib) are developing these days. To evaluate the efficacy of NOV120101
      (Poziotinib) as a first-line monotherapeutic medication, chemotherapy-na√Øve patients will
      participate in this study. Subjects will receive NOV120101 (Poziotinib) 16 mg PO once daily
      until disease progression or unacceptable toxicity development. Objective response rate
      (ORR) will be analyzed as the primary endpoint in this trial. Secondary endpoints including
      PFS rate at 12 months, DCR, PFS, and OS will also be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>about 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>the proportion of patients with complete response (CR) and/or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rate  at 12 months</measure>
    <time_frame>12 months after enrollment of the last subject</time_frame>
    <safety_issue>No</safety_issue>
    <description>the proportion of patients with complete response (CR) and/or partial response (PR) at 12 months following start of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>the proportion of patients with CR, PR and/or stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The length of time during and after medication or treatment during which the disease being treated (usually cnacer) does not get worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>the time from study drug administration until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life (QoL) measured by EQ-5D questionnaire</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change means the end of treatment minus baseline in each patient</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Population pharmacokinetics (PK) of NOV120101 (Poziotinib)</measure>
    <time_frame>3 months after enrollment of the last subject</time_frame>
    <safety_issue>No</safety_issue>
    <description>to observe pharmacokinetic parameter, inter-individual variability and intra-individual variability considering covariates, demographic factors, influencing PK profile.</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup analyses according to the genetic information</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>to observe HGF expression status in plasma and T790M mutation induction status from plasma DNA</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Adenocarcinoma of Lung Stage IIIB</condition>
  <condition>Adenocarcinoma of Lung Stage IV</condition>
  <arm_group>
    <arm_group_label>NOV120101 (Poziotinib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study with NOV120101(poziotinib)16mg PO daily administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOV120101 (Poziotinib)</intervention_name>
    <description>NOV120101 (Poziotinib)16 mg PO once daily until disease progression or unacceptable toxicity development</description>
    <arm_group_label>NOV120101 (Poziotinib)</arm_group_label>
    <other_name>HM781-36B</other_name>
    <other_name>Poziotinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients aged 20 years or older

          2. Pathologically confirmed stage IIIB (unresectable) or IV lung adenocarcinoma

          3. Documented EGFR mutation (e.g., exon 19 deletion, exon 21 L858R, etc.) with tumor
             tissue

          4. Patients who have 1 or more measurable lesions according to RECIST version 1.1

          5. ECOG performance status 2 or less

          6. Life expectancy of 12 weeks or more

          7. Patients who have adequate hematological, hepatic and renal functions; WBC 4,000 or
             more per mm3, platelet 100,000 or more per mm3, serum creatinine 1.5 times or less
             upper limit of normal, AST and ALT 2.5 times or less upper limit of normal, total
             bilirubin 1.5 times or less upper limit of normal

          8. Patients who give written informed consent voluntarily

        Exclusion Criteria:

          1. Prior systemic chemotherapy, immunotherapy or biological therapy for stage IIIB or IV
             adenocarcinoma (However, neo or adjuvant chemo, chemoradio or radiotherapy is
             permitted if at least 6 months has elapsed prior to disease progression)

          2. Prior treatment with small molecules or antibodies targeting EGFR

          3. Patients who received major surgery within 4 weeks before study drug administration

          4. Symptomatic CNS metastases (patients with radiologically and neurologically stable
             metastases and being off corticosteroids for at least 2 weeks are able to participate
             in this trial.)

          5. History of other malignancies except effectively treated non-melanoma skin cancers,
             carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated
             malignancy that has been in remission for 3 years or more and considered to be cured
             by investigator's judgment

          6. Known preexisting interstitial lung disease (ILD)

          7. NYHA class III or IV heart failure, uncontrolled hypertension, unstable angina or
             myocardial infarction within 6 months, poorly controlled arrhythmia or other
             clinically significant cardiovascular abnormalities at investigator's discretion

          8. Patients whose left ventricle ejection fraction (LVEF) is below the institutional
             lower limit of normal (if no lower limit of normal is defined in the site, the lower
             limit is 50 percent)

          9. Patients with known active hepatitis B, HIV infection, or other uncontrolled
             infectious disease

         10. Clinically significant or recent acute gastrointestinal disorders with diarrhea as a
             major symptom (e.g., Crohn's disease, malabsorption disorders, CTCAE grade 2 diarrhea
             or more due to any etiology)

         11. Patients who cannot receive IP by mouth and be diagnosed with clinically significant
             gastrointestinal disorders which can prevent administration, transit or absorption of
             the study drug

         12. Pregnancy or breast feeding

         13. Women of childbearing potential (WOCBP) or men who are unwilling to use adequate
             contraception or be abstinent during the trial and for at least 2 months after the
             end of treatment

         14. Patients who received other investigational products except gefitinib and erlotinib
             within 4 weeks before participation

         15. Patients who cannot participate in this trial by investigator's judgment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jungyong Jung, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>National OncoVenture</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jungyong Kim, MD, Ph.D</last_name>
    <phone>+82-31-920-2684</phone>
    <email>jyk1949@ncc.re.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jina Jung, MA</last_name>
    <phone>+82-31-920-2776</phone>
    <email>jajung@ncc.re.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Han, MD, Ph.D</last_name>
      <email>jymama@ncc.re.kr</email>
    </contact>
    <contact_backup>
      <last_name>Lee, MD, Ph.D</last_name>
      <email>jslee@ncc.re.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jiyoun Han, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jinsoo Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heungtae Kim, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tak Yun, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngjoo Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Soohyun Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Namdong-Gu</city>
        <state>Incheon,</state>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cho, MD, Ph.D</last_name>
      <email>ekcho@gilhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Kim, MD, Ph.D</last_name>
      <email>gene2001@gilhospital.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eunkyung Cho, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yujin Kim, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heekyung Ahn, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Park, MD, Ph.D</last_name>
      <email>kpark@skku.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ahn, MD, Ph.D</last_name>
      <email>silkahn@skku.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Keunchil Park, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Myungju Ahn, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yeonhee Park, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeeyun Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jongmu Sun, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Jongno-gu</city>
        <state>Seoul</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim, MD, Ph.D</last_name>
      <email>kimdw@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Heo, MD, Ph.D</last_name>
      <email>heo1013@snu.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Dongwan Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daeseog Heo, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sehoon Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Taemin Kim, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bhumsuk Kim, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seil Go, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Younak Choi, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seunghoon Beom, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>JaeJoon Han, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Youngjun Cha, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <zip>136-738</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee, MD, Ph.D</last_name>
      <email>leedaeho@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Kim, MD, Ph.D</last_name>
      <email>swkim@amc.seoul.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Sangwe Kim, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daehoo Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jungshin Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jaecheol Lee, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Changmin Choi, MD, Ph.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Dong-gu</city>
        <state>Ulsan</state>
        <zip>682-714</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min, MD, Ph.D</last_name>
      <email>yjmin65@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Youngjoo Min, MD, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 24, 2013</lastchanged_date>
  <firstreceived_date>March 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR mutation</keyword>
  <keyword>Lung Adenocarcinoma</keyword>
  <keyword>Firstline therapy</keyword>
  <keyword>Second generation of tyrosine kinase</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
